drugset / Trial / NCT02073019

A Phase I Study Evaluating Safety, Tolerability, PK and PD of BL-8040 for Stem Cell Mobilization in Healthy Volunteers

NCT02073019 ↗

Phase 1 Completed 33 enrolled BioLineRx, Ltd.
RandomizedParallel-groupTriple-blind

Summary

The purpose of this study is to determine whether BL-8040 is safe, tolerable and effective in the mobilization of Hematopoietic Stem Cells (HSC) in healthy volunteers

Timeline

Start
2014-08
Primary completion
2015-07
Completion
2015-07

Outcome

Met primary endpoint

release “BL-8040 Phase 1 study met all safety and efficacy endpoints” biolinerx.com ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Motixafortide Peptide — —